Table 3.
Quality appraisal of Clinical Practice Guidelines for Duchenne muscular dystrophy using the AGREE-II instrument.
| CPG | AGREE-II domains | ||||||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | Overall assessment | |
| NICE, 2016 | 37.5% | 40.2% | 75% | 59.7% | 56.2% | 60.4% | 54.8% |
| AAN, 2016 | 90.2% | 51.4% | 86.5% | 84.7% | 61.5% | 85.4% | 76.6% |
| Colombian CPG, 2015 | 100% | 95.8% | 96.4% | 97.2% | 97.9% | 100% | 97.9% |
| Australian CPG, 2020 | 80.6% | 63.9% | 72.9% | 87.5% | 46.9% | 44% | 66% |
NICE, National Institute for Clinical Excellence; AAN, American Academy of Neurology; MINSA COL, Ministerio de Salud de Colombia; 1: Scope and purpose; 2: Stakeholder involvement; 3: Rigor of development; 4: Clarity and presentation; 5: Applicability; 6: Editorial independence.
Values >80% are bolded and represent good quality.